The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains rocky, communication is patchy, and the wider impact on access and innovation is still murky. Writing in DIA’s Global Forum magazine, Grammati Sarri, Lilia Leisle,…
Featured Content
As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while domestic companies are scaling capabilities…
Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its claim as a global R&D…
In the global pharmaceutical supply chain, one small Caribbean island punches far above its weight. The US jurisdiction of Puerto Rico – just 100 miles by 35 miles – out-exports every individual US state in biopharmaceuticals, shipping over USD 53 billion worth of medicines and medical devices annually to 120 countries. That’s more than twice…
In Conversation
Virve Sarja – Head of EMEA & Executive Vice President, Varian
We are not just imagining a world without the fear of cancer; we are actively building it.
Etienne Tichit – General Manager and Corporate Vice President, Novo Nordisk France
This holistic approach creates value across the entire healthcare ecosystem whilst addressing some of society's most pressing health challenges.
Jennifer Hawks Bland – CEO, NewYorkBIO
Over the past decade, the public sector has shown a more intentional commitment to New York’s life sciences sector, creating a broader, more cohesive support system.
Mauricio Claverí – Chief Economist, CILFA
Argentina’s strongest calling card is quality, our medicines are both price-competitive and internationally recognised.
Peter Justesen – President, Hearing Division, GN
Our job is to make solutions so compelling that people want to wear them, and to ensure hearing health is seen not as a luxury, but as a fundamental part of wellbeing.
BMS Neuroscience Lead Talks New Approaches to Alzheimer's R&D
By pursuing both fronts, disease modification and symptom management, we aim to deliver a more comprehensive and humane approach [to Alzheimer's Disease]
Javier Deida – Regional Business Director and Country Lead, Pfizer Puerto Rico
What I’ve seen here is a collective mindset that consistently puts patients first, something I didn’t experience elsewhere.
John ZHU – Founder, CEO, and Chairman, Duality Biotherapeutics
Drug assets are not like wine, they need to be in the right hands to realise their full potential.
Op-Eds
InFocus
At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper, however, and its distinctive and differentiated offering becomes ever more apparent. “While Hong Kong’s biomedical ecosystem certainly still lags behind more established life sciences…
In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team of clinicians and scientists at the Chinese University of Hong Kong (CUHK), Prince of Wales Hospital, and the Hong Kong Institute of Biotechnology (HKIB), the…
With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city, with its unique background context and characteristics, to play a role shaping the next wave of biomedicine discovery. Dr Tak Wah Mak, co-director of…
Hong Kong’s unique history as a former British governate and current special status under the ‘one country, two systems’ administrative framework, endow it with many underlying advantages as a ‘talent magnet.’ From a professional standpoint, the city’s international connectivity, financial architecture, and efficient infrastructure already render it an appealing location for young entrepreneurs, not to…
